Aug 6, 2026 06:55AM
Aug 5, 2026 07:00AM
Jul 23, 2026 04:06PM
Jul 23, 2026 04:05PM
Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Jul 22, 2026 06:30AM Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial
Jul 22, 2026 06:30AM
Jun 1, 2026 02:53AM
May 31, 2026 09:06AM
May 30, 2026 08:00AM
May 22, 2026 06:35AM
Apr 30, 2026 04:32PM
Mar 27, 2026 08:16AM Summit Therapeutics to present ivonescimab data at ELCC 2026
Mar 27, 2026 08:15AM
Feb 26, 2026 06:45PM
Feb 23, 2026 04:05PM
Feb 2, 2026 06:50AM
Jan 30, 2026 05:41AM
Jan 29, 2026 07:30AM
Jan 29, 2026 07:30AM Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Pos

15,656 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All